亚洲日本欧美日韩高观看,香蕉免费一区二区三区,欧美激情a∨在线视频播放,国产国语在线播放视频

關(guān)鍵詞:
  首頁(yè) > 美迪醫(yī)訊 > Peregrine制藥公司推出血管靶向藥物Tarvacin  

Peregrine制藥公司推出血管靶向藥物Tarvacin

【?2004-11-29 發(fā)布?】 美迪醫(yī)訊
美迪網(wǎng)領(lǐng)先的醫(yī)療器械電子商務(wù)平臺(tái)

已經(jīng)有越來(lái)越多的資料支持使用血管靶向藥物(vascular targeting agents, VTAs),這種藥物被設(shè)計(jì)用來(lái)尋找并通過(guò)阻斷腫瘤血供來(lái)摧毀癌組織內(nèi)的血管生成。

血管靶向藥物的作用機(jī)制不同于廣為人知的血管生成抑制劑(angiogenesis inhibitors),血管生成抑制劑通過(guò)切斷新血管的形成來(lái)減緩腫瘤生長(zhǎng)。美國(guó)德克薩斯州西南醫(yī)療中心(Dallas,TX,USA)的Jin He博士最近在他的研究中報(bào)道說(shuō):放射治療能夠顯著增加一種被命名為3G4的Tarvacin等價(jià)物的抗腫瘤活性。Tarvacin是由Peregrine制藥公司(Peregrine Pharmaceuticals,Tustin,CA,USA)研制成功的血管靶向藥物。使用3G4聯(lián)合外源性輻射治療實(shí)驗(yàn)動(dòng)物,結(jié)果腫瘤生長(zhǎng)速度下降了98%,而單獨(dú)使用放射治療或者3G4治療分別是85%和67%。

2004年11月在美國(guó)劍橋(Cambridge,MA,USA)舉行的血管靶向藥物會(huì)議的展示會(huì)上,Peregrine制藥公司的Philip Thorpe博士評(píng)論說(shuō):“血管靶向藥物正從臨床前研究階段進(jìn)展到了臨床試驗(yàn)階段。這次會(huì)議很特別,因為會(huì)議聚集了各領(lǐng)域的專家。這樣我們可以親自討論研究項(xiàng)目、互相學(xué)習(xí)、產(chǎn)生新的理念、并將這些新理念融會(huì)貫通,然后帶回實(shí)驗(yàn)室,并最終進(jìn)入臨床應(yīng)用。”

Peregrine制藥公司致力于研究癌癥治療與診斷藥物,包括血管靶向藥物、抗血管生成藥物、促進(jìn)血管滲透性藥物(vasopermeation enhancement agents, VEAs)。該公司與美國(guó)食品藥品管理局(FDA)緊密合作,開(kāi)展了首次Tarvacin臨床試驗(yàn)。Tarvacin是一種抗體,結(jié)合于磷脂酰絲氨酸磷脂,直接結(jié)合于腫瘤血管從而抑制腫瘤的生長(zhǎng)形成。

Vascular Targeting Reduces Tumor Growth by 98%
 
A growing body of practical data supports the use of vascular targeting agents (VTAs), which are
designed to seek and destroy preexisting blood vessels within cancerous tumors by blocking off the tumor’s blood supply.

VTAs represent a therapeutic approach that is different from the more widely known angiogenesis inhibitors, which slow tumor growth by cutting off new blood vessel formation. Dr. Jin He, from the University of Texas Southwestern Medical Center (Dallas, TX, USA) has recently reported in his studies that radiation therapy had significantly increased the antitumor activity of a Tarvacin equivalent named 3G4. Tarvacin is a VTA developed by Peregrine Pharmaceuticals (Tustin, CA, USA;). In lab animals treated with 3G4 plus external beam radiation, tumor growth was reduced by 98% as compared with 85% for radiation therapy alone or 67% with 3G4 alone.

At a presentation at the Vascular Targeting Agents conference in Cambridge (MA, USA) in November 2004, Philip Thorpe, Ph.D., a member of Peregrine Pharmaceuticals remarked, “VTAs are progressing through preclinical development and into clinical trials. This conference is unique in that it brings together experts in all of the various approaches--we can discuss the research in person, learn from each other and take new ideas coming out of that mix back to the lab, and ultimately, to the clinic.”

Peregrine Pharmaceuticals develops cancer therapeutics and diagnostics including VTAs, and anti-angiogenesis and vasopermeation enhancement agents (VEAs). The company is working closely with the U.S. Food and Drug Administration (FDA) to start its first clinical trial using Tarvacin. Tarvacin is an antibody that binds to the phospholipid phosphatidylserine, which binds directly to tumor blood vessels to inhibit tumor growth and development.

收藏本文到: Digg Live Bookmark Facebook 百度搜藏 新浪ViVi 365Key網(wǎng)摘 天極網(wǎng)摘 和訊網(wǎng)摘 POCO網(wǎng)摘 QQ書(shū)簽

  《美迪醫(yī)訊》歡迎您參與新聞投稿,業(yè)務(wù)咨詢: 美迪醫(yī)療網(wǎng)業(yè)務(wù)咨詢

我要評(píng)論:《Peregrine制藥公司推出血管靶向藥物Tarvacin》
匿名發(fā)表 我的名字: Email: 驗(yàn)證碼: 點(diǎn)擊可刷新
 
    

  更多關(guān)于 血管靶向藥物,Peregrine制藥公司  的新聞

《上海醫(yī)療器械批發(fā)》產(chǎn)品推薦
斯曼峰電動(dòng)吸引器YX932D
斯曼峰電動(dòng)吸引器YX932D

廠價(jià):¥1299元
雅博防褥瘡充氣床墊DOMUS 2
雅博防褥瘡充氣床墊DOMUS 2

廠價(jià):¥1800元
棱牌(米沙瓦)一次性使用無(wú)菌注射器
棱牌(米沙瓦)一次性使用無(wú)菌注射器

廠價(jià):¥60元
滬通高頻電刀GD350-B
滬通高頻電刀GD350-B

廠價(jià):¥30800元
斯曼峰電動(dòng)洗胃機(jī)DXW-A
斯曼峰電動(dòng)洗胃機(jī)DXW-A

廠價(jià):¥3000元
康德萊一次性使用無(wú)菌注射針30G
康德萊一次性使用無(wú)菌注射針30G

廠價(jià):¥0.35元
德國(guó)貝朗動(dòng)靜脈留置針I(yè)ntrocan-W英初康 帶翼
德國(guó)貝朗動(dòng)靜脈留置針I(yè)ntrocan-W英初康 帶翼

廠價(jià):¥6.8元
飛利浦自動(dòng)體外除顫器HS1
飛利浦自動(dòng)體外除顫器HS1

廠價(jià):¥39000元
合作支持:中華醫(yī)學(xué)會(huì) | 中華醫(yī)院管理學(xué)會(huì) | 國(guó)家食品藥品監(jiān)督管理家用護(hù)理器械商城 | 國(guó)藥勵(lì)展展覽有限責(zé)任公 | 醫(yī)學(xué)裝備協(xié)會(huì)
刊登廣告 | 友情鏈接 | 廣告代理商加盟 | 關(guān)于美迪 | 法律聲明 | 隱私保護(hù) | 網(wǎng)站地圖
把美迪網(wǎng)放進(jìn)收藏夾  把美迪醫(yī)療網(wǎng)介紹給我的朋友  給美迪醫(yī)療網(wǎng)留言
美迪醫(yī)療網(wǎng)廣告業(yè)務(wù)聯(lián)系:021-51601230 產(chǎn)品咨詢業(yè)務(wù)聯(lián)系:021-51601230 傳真:021-56532303    美迪醫(yī)療網(wǎng)業(yè)務(wù)咨詢
互聯(lián)網(wǎng)藥品信息服務(wù)許可證:(滬)-經(jīng)營(yíng)性-2009-0003   中華人民共和國(guó)電信與信息服務(wù)業(yè)務(wù)經(jīng)營(yíng)許可證:(滬)B2-20090029 滬ICP備14001091號(hào)-8
 
公安備案號(hào) 31010602000199 醫(yī)療器械經(jīng)營(yíng)許可證: 滬靜藥監(jiān)械經(jīng)營(yíng)許20210003號(hào) 第二類醫(yī)療器械經(jīng)營(yíng)備案憑證: 滬靜藥監(jiān)械經(jīng)營(yíng)備20220042號(hào)
營(yíng)業(yè)執(zhí)照:統(tǒng)一社會(huì)信用代碼91310108676284138X互聯(lián)網(wǎng)藥品信息服務(wù)資格書(shū):(滬)-非經(jīng)營(yíng)性-2023-0081
消防排煙風(fēng)機(jī) 華創(chuàng)商務(wù)網(wǎng)
美迪醫(yī)療網(wǎng)廣告業(yè)務(wù)聯(lián)系:021-51601230  產(chǎn)品咨詢業(yè)務(wù)聯(lián)系:021-51601230 傳真:021-56532303   美迪醫(yī)療網(wǎng)產(chǎn)品咨詢 本QQ僅咨詢廣告和會(huì)員業(yè)務(wù),不咨詢產(chǎn)品和藥品等業(yè)務(wù)美迪醫(yī)療網(wǎng)推廣業(yè)務(wù)咨詢